Tourmaline Bio, Inc. (TRML)
US — Healthcare Sector
Peers:
Automate Your Wheel Strategy on TRML
With Tiblio's Option Bot, you can configure your own wheel strategy including TRML - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TRML
- Rev/Share 0.0016
- Book/Share 10.893
- PB 1.5597
- Debt/Equity 0.0007
- CurrentRatio 33.8683
- ROIC -0.3515
- MktCap 436447615.0
- FreeCF/Share -3.2709
- PFCF -5.1935
- PE -5.2674
- Debt/Assets 0.0007
- DivYield 0
- ROE -0.2675
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TRML | Chardan Capital Markets | -- | Buy | -- | $70 | April 23, 2025 |
| Initiation | TRML | Wedbush | -- | Outperform | -- | $42 | March 6, 2025 |
| Initiation | TRML | BMO Capital Markets | -- | Outperform | -- | $50 | Dec. 6, 2024 |
News
Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition
TRML
Published: May 20, 2025 by: Seeking Alpha
Sentiment: Positive
Published: May 20, 2025 by: Seeking Alpha
Sentiment: Positive
Pacibekitug showed statistically significant hs-CRP reduction in CKD patients in the phase 2 TRANQUILITY study, establishing proof-of-concept for IL-6 inhibition. Positive data supports advancing pacibekitug to a phase 3 cardiovascular outcomes trial for ASCVD, pending an FDA meeting in late 2025. The 7 major Atherosclerotic Cardiovascular Disease markets are expected to reach $30.6 billion by 2035.
Read More
About Tourmaline Bio, Inc. (TRML)
- IPO Date 2021-05-07
- Website https://www.tourmalinebio.com
- Industry Biotechnology
- CEO Dr. Sandeep C. Kulkarni M.D.
- Employees 74
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.